Dr. McQuade on Age as a Predictor of Response to Neoadjuvant Immunotherapy in Melanoma

Jennifer McQuade, MD, MS, MA, LAc
Published: Saturday, Dec 14, 2019



Jennifer McQuade, MD, MS, MA, LAc, assistant professor and physician scientist, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses how age may serve as a predictor of response to neoadjuvant immunotherapy for patients with melanoma.
 
McQuade notes that some host factors including age demonstrate contradictory responses to immunotherapy.
 
Preclinical trials with mice and various neoadjuvant trials have shown that older patients had an improved response to immunotherapy despite being a generally more immune-suppressed population, concludes McQuade.
SELECTED
LANGUAGE


Jennifer McQuade, MD, MS, MA, LAc, assistant professor and physician scientist, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses how age may serve as a predictor of response to neoadjuvant immunotherapy for patients with melanoma.
 
McQuade notes that some host factors including age demonstrate contradictory responses to immunotherapy.
 
Preclinical trials with mice and various neoadjuvant trials have shown that older patients had an improved response to immunotherapy despite being a generally more immune-suppressed population, concludes McQuade.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x